SHANGHAI – China Biologic Inc., of Beijing, has topped up its controlling equity interest by 20 percent in Guizhou Taibang Biological Products Co. Ltd., in a deal valued at $87.1 million.
SHANGHAI – Hutchison China Meditech Ltd., also known as Chi-Med, said this month that phase III trials would be terminated for its lead candidate, HMPL-004, a botanical treatment for ulcerative colitis (UC).
SHANGHAI – China Biologic Inc., of Beijing, has topped up its controlling equity interest by 20 percent in Guizhou Taibang Biological Products Co. Ltd., in a deal valued at $87.1 million.
SHANGHAI – Innovent Biologics Inc. and its staff of 170 took occupancy of its $140 million facility in Suzhou's Biobay Industrial Park this month. The impressive facility designed with ancient fengshui principles in mind, houses two state-of-the-art 1,000-liter bioreactors.
SHANGHAI – Newly minted Zai Lab Ltd., of Shanghai, has made its eagerly awaited debut announcement, obtaining global rights to two Sanofi SA preclinical compounds for chronic respiratory diseases.
SHANGHAI – Privately held Huya Bioscience International, of San Diego, has signed a strategic partnership with the Changzhou Center for Biotech Development (CZCBD) for the advancement of innovative drug and biomarker candidates.
SHANGHAI – Newly minted Zai Lab Ltd., of Shanghai, has made its eagerly awaited debut announcement, obtaining global rights to two Sanofi SA preclinical compounds for chronic respiratory diseases.
SHANGHAI – Sotio AS, of Prague, has expanded its China footprint with the opening of a GMP, clean-room lab for the production of active cellular immunotherapy treatments against cancer diseases.
